{"url":"https://newsforagent.com/news/2026-11-04/aribio-mirodose-mrc-ar1001-study","markdown_url":"https://newsforagent.com/news/2026-11-04/aribio-mirodose-mrc-ar1001-study.md","title":"AriBio Backs £2.1 Million MRC Study of AR1001 in Small Vessel Disease","headline":"AriBio Joins Imperial College London's MiroDose Study of AR1001 With £2.1 Million MRC Funding","description":"AriBio will supply AR1001 and run pharmacokinetic analyses for Imperial College London's MiroDose study.","section":"Partnerships","published_at":"2026-11-04T21:56:56+00:00","modified_at":"2026-11-04T21:56:56+00:00","author":"News Desk","key_takeaways":["AriBio is the industry partner on MiroDose, an investigator-initiated study of AR1001 in cerebral small vessel disease led by Imperial College London.","The Medical Research Council awarded about £2.1 million to Imperial College London to support the study.","MiroDose plans to enroll 82 participants in a randomized, double-blind, placebo-controlled crossover design.","AriBio's global Phase 3 POLARIS-AD trial of AR1001 in early Alzheimer's disease enrolled 1,535 participants across 13 countries."],"companies":[{"name":"AriBio","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000v7p/aribio","website":"http://www.aribio.com"}],"source":{"publisher":"EIN Presswire","title":"AriBio Announces MRC-Funded UK Academic Collaboration to Investigate AR1001 in Cerebral Small Vessel Disease","url":"https://www.einnews.com/pr_news/954560860/aribio-announces-mrc-funded-uk-academic-collaboration-to-investigate-ar1001-in-cerebral-small-vessel-disease"},"other_sources":[],"tags":["Partnerships","AriBio"],"body_markdown":"[AriBio](https://akta.pro/company-profiles/0000v7p/aribio) will supply AR1001 and matched placebo for MiroDose, an investigator-initiated study of cerebral small vessel disease at Imperial College London, supported by about £2.1 million from the UK Medical Research Council. The South Korean clinical-stage biotechnology company announced the collaboration on November 4, 2026, according to [EIN Presswire](https://www.einnews.com/pr_news/954560860/aribio-announces-mrc-funded-uk-academic-collaboration-to-investigate-ar1001-in-cerebral-small-vessel-disease).\n\n## How the MiroDose Study Will Run\n\nImperial College London sponsors MiroDose, and researchers at Imperial and City St George's, University of London take part. The randomized, double-blind, placebo-controlled crossover study plans to enroll 82 participants with MRI-confirmed cerebral small vessel disease. Researchers will use advanced MRI, physiological assessments, blood biomarkers and cognitive testing to examine dose-related effects on cerebral blood flow, cerebrovascular reactivity and blood-brain barrier function.\n\nAriBio's role as industry partner covers supplying AR1001 and matched placebo and conducting pharmacokinetic analyses that measure mirodenafil and key metabolites in participant samples. The company will also contribute drug development expertise. The study examines how inhibition of phosphodiesterase type 5 affects cerebral blood flow and vascular function, generating mechanistic evidence intended to inform possible future development of AR1001 for vascular cognitive impairment and dementia.\n\nProfessor Alastair Webb, Clinical Professor of Cerebrovascular Disease at Imperial College London, leads the study. Professor Atticus Hainsworth, Professor of Cerebrovascular Disease at City St George's, University of London, is part of the collaboration. Webb said: \"This collaboration between Imperial College and AriBio provides a fantastic opportunity to understand the role of endothelial dysfunction and PDE5 inhibition in cerebral small vessel disease.\"\n\nJai Jun Choung, Ph.D., Chairman and Chief Executive Officer of AriBio, said: \"Through this collaboration, AriBio is contributing both AR1001 and the pharmacokinetic expertise needed to connect drug exposure with changes in cerebrovascular function.\" AR1001 (mirodenafil) is an investigational oral small molecule and a brain-penetrant PDE5 inhibitor. Its safety and efficacy for Alzheimer's disease, cerebral small vessel disease and other dementia indications have not been established.\n\n## AriBio's AR1001 Deal Record\n\nAriBio signed an exclusive global option agreement with Fosun Pharma for AR1001 in May 2026, extending an earlier regional deal to the U.S., Europe and Japan, according to [akta.pro company records](https://akta.pro/company-data). The records put total potential deal value at about $4.7 billion, with $60 million upfront, up to $180 million in milestones and tiered double-digit royalties tied to $2.5 billion annual net sales thresholds. The same records list a $7.5 million corporate funding round in July 2026 led by Fosun Pharma.\n\n## Earlier AR1001 Milestones\n\nAriBio completed the treatment phase of its global Phase 3 POLARIS-AD trial of AR1001 in early Alzheimer's disease, enrolling 1,535 patients across 13 countries, EIN Presswire reported in August 2026. In July 2026, Aribio received the full $50 million advance payment from Pushing Pharmaceutical under a global exclusive rights contract for AR1001, bringing total option fees secured to $60 million, according to Nate. Seeking Alpha reported in October 2026 that AriBio will announce Phase 3 trial results for AR1001 within a month.\n\n## MiroDose Within the MRC Programme\n\nMiroDose is one of five experimental medicine studies supported by a broader £16.5 million MRC investment in dementia research.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}